



(51) International Patent Classification:

A61K 39/12 (2006.01) C07K 14/005 (2006.01)
A61K 39/145 (2006.01) C12N 15/86 (2006.01)
A61P 31/16 (2006.01)

(21) International Application Number:

PCT/IB2024/051087

(22) International Filing Date:

06 February 2024 (06.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/484,186	09 February 2023 (09.02.2023)	US
63/484,747	13 February 2023 (13.02.2023)	US
63/621,102	15 January 2024 (15.01.2024)	US

(71) Applicant: **PFIZER INC.** [US/US]; 66 Hudson Boulevard East, New York, New York 10001-2192 (US).

(72) Inventors: **ALLEN, Pirada Suphaphiphat**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US). **CHE, Ye**; 15 Freedom Way #5, Niantic, Connecticut 06357 (US). **MUNOZ-MORENO, Raquel**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US). **SOLORZANO QUIJANO, Alicia**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; PFIZER INC., 100 Route 206 North, Mail Stop: SOM-PPK4-LLA-403, Peapack, New Jersey 07977 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: NUCLEIC ACIDS AND USES THEREOF




FIG. 14

(57) Abstract: Self-amplifying RNA (saRNA) molecules encoding an influenza virus antigen and methods of use thereof are disclosed herein.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*